Gardasil vs Cervarix: Se conocen ya resultados...Cervarix "gana."

Alertamos...ahora se conocen ya resultados y, de momento, dan "ganador" a Glaxo.

LONDON -- Drugmaker GlaxoSmithKline said Friday that results from the first, large-scale comparative trial between licensed human papillomavirus vaccines show that GSK's Cervarix generated a significantly higher immune response compared to Merck & Co's Gardasil. The trial showed neutralising antibody levels for Cervarix vaccine were more than two times higher than those for Gardasil vaccine for HPV type 16, and more than six times higher for HPV type 18, GSK said. These results were highly statistically significant, it added.

Ver...

Nevertheless, U.K.-based Glaxo hopes the results, to be presented at a Swedish medical conference that begins Friday, will help give Cervarix a competitive edge if it reaches the U.S. market, which Merck has had to itself since Gardasil's launch in 2006. The U.S. Food and Drug Administration is reviewing Cervarix and could decide whether to allow it to go on sale by autumn. Cervarix is already on the market in other countries including the U.K.

"The study clearly shows a higher level of immune response in women receiving Cervarix than Gardasil," Gary Dubin, vice president of global clinical development in Glaxo's vaccine unit, told Dow Jones Newswires in an interview.

Mas...